Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Death/intubation -4% Improvement Relative Risk HCQ for COVID-19  Geleris et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,446 patients in the USA No significant difference in death/intubation c19hcq.org Geleris et al., NEJM, May 7, 2020, May 2020 Favors HCQ Favors control

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Geleris et al., NEJM, May 7, 2020, doi:10.1056/NEJMoa2012410
May 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Before propensity matching, 38 control patients had hypertension. After propensity matching, 146 patients had hypertension (Table 1). Even if all propensity matched control patients had hypertension, the control prevalence would only be 14% compared to 49% for treatment. Since patients with hypertension are at much greater risk of mortality (HR 2.12, see academic.oup.com), this appears to invalidate the results.
Observational study of 1,446 hospitalized patients showing no significant effect on a combined intubation/death outcome for late treatment.
However, secondary analysis shows the success of HCQ was hidden by combining intubation and death - death / (combined death/intubation) for HCQ was 60% vs. control 89%, for details see: twitter.com.
RCT recommended. No AZ or Zinc. HCQ group much sicker - patients already in mild/moderate ARDS, most of the control group not in ARDS. Control cases received other therapeutics.
This study is excluded in the after exclusion results of meta analysis: significant issues found with adjustments.
risk of death/intubation, 4.0% higher, HR 1.04, p = 0.76, treatment 262 of 811 (32.3%), control 84 of 565 (14.9%), adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Geleris et al., 7 May 2020, retrospective, USA, peer-reviewed, 12 authors.
This PaperHCQAll
Abstract: The n e w e ng l a n d j o u r na l of m e dic i n e Original Article Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Joshua Geleris, M.D., Yifei Sun, Ph.D., Jonathan Platt, Ph.D., Jason Zucker, M.D., Matthew Baldwin, M.D., George Hripcsak, M.D., Angelena Labella, M.D., Daniel K. Manson, M.D., Christine Kubin, Pharm.D., R. Graham Barr, M.D., Dr.P.H., Magdalena E. Sobieszczyk, M.D., M.P.H., and Neil W. Schluger, M.D.​​ A BS T R AC T BACKGROUND Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses. From the Divisions of General Medicine, Infectious Diseases, and Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., N.W.S.), the Departments of Biostatistics (Y.S.) and Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public Health, and the Department of Biomedical Informatics (G.H.), Vagelos College of Physicians and Surgeons, Columbia University, and New York–Presbyterian Hospital–Columbia University Irving Medical Center (J.G., J.Z., M.B., A.L., D.K.M., C.K.,R.G.B., M.E.S., N.W.S.) — all in New York. Address reprint requests to Dr. Schluger at the Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, PH-8 E., Rm. 101, 622 W. 168th St., New York, NY 10032, or at ­ns311@​­cumc​.­columbia​.­edu. This article was published on May 7, 2020, and updated on May 14, 2020, at NEJM.org. N Engl J Med 2020;382:2411-8. DOI: 10.1056/NEJMoa2012410 Copyright © 2020 Massachusetts Medical Society. CONCLUSIONS In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was..
{ 'DOI': '10.1056/nejmoa2012410', 'ISSN': ['0028-4793', '1533-4406'], 'URL': 'http://dx.doi.org/10.1056/NEJMoa2012410', 'alternative-id': ['10.1056/NEJMoa2012410'], 'author': [ { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Geleris', 'given': 'Joshua', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Sun', 'given': 'Yifei', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Platt', 'given': 'Jonathan', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Zucker', 'given': 'Jason', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Baldwin', 'given': 'Matthew', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Hripcsak', 'given': 'George', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Labella', 'given': 'Angelena', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Manson', 'given': 'Daniel K.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Kubin', 'given': 'Christine', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Barr', 'given': 'R. Graham', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Sobieszczyk', 'given': 'Magdalena E.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'From the Divisions of General Medicine, Infectious Diseases, and ' 'Pulmonary, Allergy, and Critical Care Medicine, Department of ' 'Medicine (J.G., J.Z., M.B., A.L., D.K.M., C.K., R.G.B., M.E.S., ' 'N.W.S.), the Departments of Biostatistics (Y.S.) and ' 'Epidemiology (J.P., R.G.B., N.W.S.), Mailman School of Public ' 'Health, and the Department of Biomedical Informatics (G.H.), ' 'Vagelos College of Physicians and Surgeons, Columbia University, ' 'and New York–Presbyterian Hospital–Columbia University Irving ' 'Medical Center ...'}], 'family': 'Schluger', 'given': 'Neil W.', 'sequence': 'additional'}], 'container-title': 'New England Journal of Medicine', 'container-title-short': 'N Engl J Med', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2020, 5, 7]], 'date-time': '2020-05-07T21:00:58Z', 'timestamp': 1588885258000}, 'deposited': { 'date-parts': [[2020, 6, 17]], 'date-time': '2020-06-17T20:57:58Z', 'timestamp': 1592427478000}, 'funder': [ { 'DOI': '10.13039/100000002', 'award': ['RO1-HL077612', 'RO1-HL093081', 'RO1-HL121270', 'RO1-LM006910'], 'doi-asserted-by': 'publisher', 'name': 'National Institutes of Health'}, { 'DOI': '10.13039/100005258', 'award': ['200-2009-32593'], 'doi-asserted-by': 'publisher', 'name': 'National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention'}], 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T07:53:50Z', 'timestamp': 1712562830438}, 'is-referenced-by-count': 1208, 'issue': '25', 'issued': {'date-parts': [[2020, 6, 18]]}, 'journal-issue': {'issue': '25', 'published-print': {'date-parts': [[2020, 6, 18]]}}, 'language': 'en', 'license': [ { 'URL': 'http://www.nejmgroup.org/legal/terms-of-use.htm', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 6, 18]], 'date-time': '2020-06-18T00:00:00Z', 'timestamp': 1592438400000}}], 'link': [ { 'URL': 'http://www.nejm.org/doi/pdf/10.1056/NEJMoa2012410', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '150', 'original-title': [], 'page': '2411-2418', 'prefix': '10.1056', 'published': {'date-parts': [[2020, 6, 18]]}, 'published-print': {'date-parts': [[2020, 6, 18]]}, 'publisher': 'Massachusetts Medical Society', 'reference': [ {'DOI': '10.1021/jm0601856', 'doi-asserted-by': 'publisher', 'key': 'r1'}, {'DOI': '10.1016/S0049-0172(10)80012-5', 'doi-asserted-by': 'publisher', 'key': 'r2'}, {'DOI': '10.1016/j.ijantimicag.2020.105938', 'doi-asserted-by': 'publisher', 'key': 'r3'}, {'DOI': '10.1016/j.ijantimicag.2020.105960', 'doi-asserted-by': 'publisher', 'key': 'r4'}, {'DOI': '10.1016/j.ijantimicag.2020.105949', 'doi-asserted-by': 'publisher', 'key': 'r6'}, {'DOI': '10.1093/cid/ciaa237', 'doi-asserted-by': 'publisher', 'key': 'r7'}, {'DOI': '10.1097/CCM.0000000000002514', 'doi-asserted-by': 'publisher', 'key': 'r8'}, {'DOI': '10.1016/j.chest.2016.01.003', 'doi-asserted-by': 'publisher', 'key': 'r9'}, {'DOI': '10.1002/9780470316696', 'doi-asserted-by': 'publisher', 'key': 'r11'}, {'DOI': '10.1001/jamanetworkopen.2020.8857', 'doi-asserted-by': 'publisher', 'key': 'r12'}, {'author': 'Chen Z', 'journal-title': 'MedRxiv', 'key': 'r13', 'year': '2020'}], 'reference-count': 11, 'references-count': 11, 'relation': { 'has-review': [ { 'asserted-by': 'object', 'id': '10.3410/f.737908482.793576143', 'id-type': 'doi'}]}, 'resource': {'primary': {'URL': 'http://www.nejm.org/doi/10.1056/NEJMoa2012410'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': [], 'title': 'Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19', 'type': 'journal-article', 'volume': '382'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit